title: Increased sensitivity to sodium salicylate-induced apoptosis in drug-resistant leukemia L1210 cells.
abstract: Mouse leukemia L1210 cells selected for resistance to deoxyadenosine contain ribonucleotide reductase that is not feedback inhibited by dATP. These deoxyadenosine-resistant cells (Y8) also do not express p53 protein but do have WAF1 and Gadd45 mRNA and protein. The Y8 cells show increased sensitivity to DNA damaging agents and kinase inhibitors. In these studies we show that in the presence of sodium salicylate (NaSal), the parental wild-type (WT) cells block in G2/M phase of the cell cycle while the Y8 cells show a marked increased in the G0/G1 population of cells. The Y8 cells are more sensitive to apoptosis induced by NaSal than the WT cells. NaSal treatment causes the induction of caspase-3-like activity in Y8 cells but no induction of caspase-3 activity in the WT cells. The caspase inhibitor, Ac-DEVD-CHO, decreased the percentage of Y8 cells in the early apoptotic fraction, but this decrease was reflected by an increase in the percent of cells in the late apoptotic/necrotic fraction. SB20358, a p38-MAP kinase inhibitor did not protect the Y8 cells from NaSal-induced apoptosis indicating that the p38-MAP kinase pathway was not involved in the NaSal-induced apoptotic pathway in the p53-independent Y8 cells.
authors: Department of Biochemistry, Brody Medical Sciences Bldg., 5E124, Brody School of Medicine, East Carolina University, Greenville, NC 27858, USA.
authors: J G
authors: JG
authors: Hall
authors: A H
authors: AH
authors: Cory
authors: D H
authors: DH
authors: Hickerson
authors: J G
authors: JG
authors: Cory
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D053148:Caspase 3; D061945:Caspase Inhibitors; D002453:Cell Cycle / Q000187:drug effects; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D003839:Deoxyadenosines / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D004791:Enzyme Inhibitors / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D007939:Leukemia L1210 / Q000473:pathology*; D051379:Mice; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors; D009842:Oligopeptides / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D012980:Sodium Salicylate / Q000494:pharmacology*; D048051:p38 Mitogen-Activated Protein Kinases
chemical_list: D061945:Caspase Inhibitors; D015853:Cysteine Proteinase Inhibitors; D003839:Deoxyadenosines; D004791:Enzyme Inhibitors; D007093:Imidazoles; D009842:Oligopeptides; D011725:Pyridines; C099158:acetyl-aspartyl-glutamyl-valyl-aspartal; D020928:Mitogen-Activated Protein Kinases; D048051:p38 Mitogen-Activated Protein Kinases; C505409:Casp3 protein, mouse; D053148:Caspase 3; C093642:SB 203580; D012980:Sodium Salicylate